Envveno Medical Corporation SEC Filings

enVVeno Medical Corp executive Hamed Alavi, the company’s Chief Technology Officer, reported a change in his equity holdings. A Form 4 filing shows that 50,000 restricted stock units were surrendered and cancelled at a price of $0. These units were originally issued on November 30, 2021 under the Amended and Restated 2016 Omnibus Incentive Plan and were subject to performance-based vesting conditions.

The filing explains that the specified performance milestones were not achieved, and therefore the unvested restricted stock units were voluntarily cancelled. Following this transaction, the number of derivative securities of this type beneficially owned by Alavi is reported as 0.

enVVeno Medical Corp executive reports cancellation of equity award. SVP & Chief Medical Officer Dr. Marc Glickman filed a beneficial ownership report showing that 100,000 restricted stock units were surrendered and cancelled after specified performance milestones tied to the award were not achieved. The units were originally granted on November 30, 2021 under the company’s Amended and Restated 2016 Omnibus Incentive Plan and a Restricted Stock Unit Agreement, and had been scheduled to expire on November 30, 2031. Following this transaction dated December 16, 2025, Dr. Glickman reports direct ownership of 1,600 shares of common stock and no remaining derivative securities from this RSU grant.

enVVeno Medical Corp director Francis Duhay reported selling 4,900 shares of common stock on December 11, 2025 at a weighted-average price of $0.3556 per share. The sale was executed in multiple trades during the day at prices ranging from $0.3554 to $0.3573. After this transaction, the director beneficially owns 92,544 shares of enVVeno Medical common stock. The filing states that the trade was completed under a Rule 10b5-1 trading plan that the reporting person adopted in June 2025, which is a pre-arranged plan for trading company stock.

enVVeno Medical Corporation reported the results of its 2025 Annual Meeting of Stockholders. A total of 11,058,255 shares of common stock were represented in person or by proxy out of 20,216,176 shares outstanding and entitled to vote as of October 17, 2025, representing 54.70% of the voting power.

Stockholders voted on the election of two directors and several additional proposals. For the board seats, Matthew M. Jenusaitis received 3,468,484 votes for and 1,796,053 votes withheld, while Robert A. Berman received 4,727,591 votes for and 536,946 votes withheld. The filing also lists detailed vote totals for four other proposals, each showing the number of votes for, against, abstentions, and broker non-votes, providing transparency into stockholder participation and preferences.

enVVeno Medical Corporation is asking stockholders to approve authority for a reverse stock split of its common stock, at a ratio between one-for-five and one-for-thirty-five, to be implemented at the Board’s discretion if approved. The company currently has 20,216,176 shares outstanding; for example, at a one-for-five ratio this would become approximately 4,043,235 shares. The Board states its main goal is to lift the share price above Nasdaq’s $1.00 minimum bid requirement after receiving notice that the stock traded below that level for 30 consecutive business days, with a recent closing price of $0.3297 per share. The reverse split would not change authorized share counts, so it would increase the pool of authorized but unissued shares, and each holder’s ownership percentage is expected to remain about the same aside from fractional-share cashouts. The Board also reduced the quorum requirement for stockholder meetings to thirty three and one-third percent of voting shares outstanding.

enVVeno Medical Corporation (NVNO) disclosed that investor Thomas A. Satterfield, Jr. has filed a Schedule 13G reporting beneficial ownership of 1,822,500 shares of common stock, representing 9.0% of the outstanding shares, based on 20,216,176 shares outstanding as of October 28, 2025. Satterfield has sole voting and dispositive power over 165,000 shares and shared voting and dispositive power over 1,657,500 shares.

The filing explains that 400,000 shares are held through Tomsat Investment & Trading Co., Inc., wholly owned by Satterfield, and 1,250,000 shares are held by Caldwell Mill Opportunity Fund, LLC, a fund managed by an entity in which he owns a 50% interest and serves as Chief Investment Manager. He certifies that the securities were not acquired for the purpose of changing or influencing control of enVVeno, indicating a passive investment stance.

Nantahala Capital Management, Wilmot B. Harkey, and Daniel Mack filed Amendment No. 2 to Schedule 13G for enVVeno Medical (NVNO). They report beneficial ownership of 688,940 shares of common stock, representing 3.46% of the class, as of September 30, 2025.

The reporting persons have shared voting and shared dispositive power over these shares, with no sole voting or dispositive power. They certify the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control.

enVVeno Medical (NVNO) reported that it received an unfavorable appeal decision from the U.S. Food & Drug Administration regarding its Premarket Approval (PMA) application for VenoValve, a surgical replacement venous valve intended to treat severe deep chronic venous insufficiency. The company disclosed this update under Regulation FD.

The announcement was furnished via an accompanying press release included as Exhibit 99.1. The filing reiterates standard forward‑looking statement cautions.

enVVeno Medical Corporation established an at-the-market equity program, allowing it to sell up to $50,000,000 of common stock from time to time through Ladenburg Thalmann as sales agent. The agent will receive a fixed 3% commission on gross proceeds from each sale. Sales may be made as “at-the-market” offerings under Rule 415, including ordinary brokers’ transactions on the NASDAQ Capital Market at market prices or as otherwise agreed. The company is not obligated to sell shares and may suspend or terminate the program.

The shares are covered by enVVeno’s effective Form S-3 (File No. 333-273546) declared effective on August 23, 2023, and a Prospectus Supplement filed on October 30, 2025. An opinion of counsel regarding the legality of the shares and the ATM Agreement were filed as exhibits.